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Background: The purpose of this study was to identify the genetic cause and describe the clinical phenotype of
Schnyder corneal dystrophy (SCD) in six unrelated probands.
Methods: We identified two white Czech, two white British and two South Asian families with a clinical diagnosis
of SCD. Ophthalmic assessment included spectral domain optical coherence tomography (SD-OCT) of one
individual with advanced disease, and SD-OCT and confocal microscopy of a child with early stages of disease.
UBIAD1 coding exons were amplified and Sanger sequenced in each proband. A fasting serum lipid profile was
measured in three probands. Paternity testing was performed in one family.
Results: A novel heterozygous c.527G>A; p.(Gly176Glu) mutation in UBIAD1 was identified in one Czech proband. In
the second Czech proband, aged 6 years when first examined, a previously described de novo heterozygous c.289G>A;
p.(Ala97Thr) mutation was found. Two probands of South Asian descent carried a known c.305G>A; p.(Asn102Ser)
mutation in the heterozygous state. Previously reported heterozygous c.361C>T; p.(Leu121Phe) and c.308C>T;
p.(Thr103Ile) mutations were found in two white British families. Although crystalline deposits were present in all
probands the affected area was small in some individuals. Corneal arcus and stromal haze were the most prominent
phenotypical feature in two probands. In the Czech probands, SD-OCT confirmed accumulation of reflective material in
the anterior stroma. Crystalline deposits were visualized by confocal microscopy. Mild dyslipidemia was found in all
three individuals tested.
Conclusion: Although de novo occurrence of mutations in UBIAD1 is extremely rare, SCD should be considered in the
differential diagnosis of bilateral corneal haze and/or crystal deposition, especially in children.
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Schnyder corneal dystrophy (SCD; MIM #121800) is a rare
autosomal dominant disorder characterized by bilateral cor-
neal opacification due to an accumulation of unesterified
cholesterol and phospholipids in the corneal stroma [1].* Correspondence: petra.liskova@lf1.cuni.cz
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(http://creativecommons.org/publicdomain/zeApproximately 50% of individuals have crystalline deposits
[2]. An association with genu valgum and systemic hyper-
lipidemia has also been reported [3].
SCD is caused by mutations in the UBIAD1 gene (MIM
*611632), encoding a membrane-embedded UbiA prenyl-
transferase domain-containing protein which catalyses the
Mg2+-dependent transfer of a hydrophobic polyprenyl
chain onto a variety of acceptor molecules, including vita-
min K and coenzyme Q [1, 4, 5]. At least 26 mutations
that cause SCD have been identified to date [6].
In this study we report the clinical and genetic investi-
gation of six probands of white and South Asian origin.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Clinical examination
The study was approved by the relevant research eth-
ics committees and adhered to the tenets of the
Helsinki Declaration. Previously unreported probands
from six families with a clinical diagnosis of SCD
were investigated; two were recruited in the Czech
Republic and four in the UK (Table 1). Family history
of SCD was documented and available family mem-
bers were invited to participate.
Ophthalmic examination included best corrected
Snellen visual acuity (BCVA) converted to decimal
values, intraocular pressure, and fundal examination
after pupil dilation. We performed corneal imaging
of probands 1 and 2 using spectral domain optical
coherence tomography (SD-OCT) (Spectralis; Heidel-
berg Engineering GmbH). Proband 2 also underwent
scanning slit confocal microscopy equipped with a
non-applanating 40× immersion objective lens (Con-
foscan 3.0; Nidek Technologies, Viconza, Italy) [7].
We measured the fasting serum lipid profile of
three probands and recorded the levels of total
cholesterol, high and low-density lipoproteins, and
triglycerides. The presence of joint deformity, scoli-
osis or learning difficulty was based on self-reported
symptoms.Table 1 Demographic and clinical data of six probands with Schnyd
No Ethnicity Family
history
UBIAD1
mutation
Age (when
recruited)/
gender
BCVA Corneal phen
LE RE
1 White
Czech
Y c.527G>A
p.(Gly176Glu)
36/M 0.6 0.7 Subepithelia
and mid-per
crystals in a
pattern, mini
corneal arcu
2 White
Czech
N c.289G>A
p.(Ala97Thr)
6/F 0.6 0.5 Subepithelia
peripheral an
mid-stromal
in a ring pat
3 White
British
Not
known
c.361C>T
p.(Leu121Phe)
10/M 0.3 0.3 Mid-stromal
crystals
4 White
British
Y c.308C>T
p.(Thr103Ile)
54/F 0.5 0.66 Central strom
arcus, few m
subepithelial
5 South
Asian
Y c.305G>A
p.(Asn102Ser)
37/F 0.66 0.66 Diffuse strom
few subepith
mid-periphe
6 South
Asian
Y c.305G>A
p.(Asn102Ser)
40/F 0.5 0.66 Central strom
arcus, few su
mid-periphe
BCVA best corrected visual acuity, LE left eye, RE right eye, BE both eyes, M male, F
lipoprotein, TG triglycerides, *- elevated but value not known, UA unavailable data
Elevated values are shown in boldMolecular genetic analysis
Genomic DNA from probands and any additional avail-
able family members was extracted from venous blood
samples using a Gentra Puregene blood kit (Qiagen,
Hilden, Germany) or from saliva using an Oragene kit
(Oragene OG-300, DNA Genotek, Canada). We then per-
formed PCR amplification and Sanger sequencing of the
two UBIAD1 coding exons and exon/intron boundaries
(primer sequences and conditions are listed in Table 2).
Variants were annotated against the reference sequence
for transcript NM_013319.2. Mutation description
followed standard nomenclature guidelines (http://varno
men.hgvs.org/) starting with nucleotide numbering c.1 at
the A of the ATG translation initiation codon. Pathogen-
icity was evaluated in silico by six different algorithms
(PROVEAN [8], SNPs&GO [9], MutPred [10], SIFT [11],
PolyPhen-2 [12] and MutationTaster [13]). We also per-
formed paternity testing in family 2, using a previously
published set of markers [14]. The population frequency of
variants was determined by the Genome Aggregation
Database (gnomAD), which provides sequencing data from
more than 123,136 exomes and 15,496 genomes from
unrelated individuals of various ethnic backgrounds [15],
and 2500 Czech control chromosomes available through
the next generation sequencing projects of the Czech
National Center for Medical Genomics (https://ncmg.cz/en).er corneal dystrophy
otype Chol
(mmol/l)
HDL
(mmol/l)
LDL
(mmol/l)
TG
(mmol/l)
Other relevant
clinical data
l central
ipheral
ring
mal
s
5.72 1.58 3.21 1.51
l mid-
d
crystals
tern
4.89 1.31 2.66 2.05
central 5.00 1.90 UA 1.80 Amblyopia in BE
Lamellar
keratoplasty in
RE and LE at the
age of 10 and
12 years
al haze,
id-peripheral
crystals
UA* UA UA UA
al haze,
elial
ral crystals
UA UA UA UA Knee deformities,
scoliosis, learning
difficulties
al haze,
bepithelial
ral crystals
UA UA UA UA
female, Chol total cholesterol, HDL high density lipoprotein, LDL low density
Table 2 Primer sequences and condition used for PCR and Sanger sequencing of UBIAD1 gene
Target Forward primer Reverse Primer Size (bp) Enzyme Annealing Temp
exon 1 CCGTCCTTCCTCCTTCCC AAGCCACCTTTGACATCCCT 700 GoTaqGreen 65 °C
exon 2 CCACCTGCACAGTCTAAGGA CTGCCAAATCACATTCCTTCCT 689 GoTaqGreen 60 °C
Fig. 1 Corneal phenotype observed in five probands with Schnyder corneal dystrophy. Ring of prominent superficial crystalline deposits in
proband 1 aged 36 years (a), also documented by SD-OCT as a discontinuous hyper-reflective line beneath the epithelium and within the
anterior corneal stroma (b). Discrete crystalline deposits in proband 2 aged 8 years (c) and more scattered opacities on SD-OCT (d).
Central mid-stromal crystalline deposits in proband 3 aged 10 years (e). Diffuse stromal haze with prominent arcus in proband 4 aged
54 years (f, g) and proband 5 aged 37 years (h). Corneal crystals (arrows) were present in all probands, although in proband 2 they were
a minor feature (b), corresponding to an early stage of the disease, and in probands 4 and 5 (g, h) they were present in only a very
small area (arrows). All images show findings in the right eye
Evans et al. BMC Ophthalmology  (2018) 18:250 Page 3 of 7
Evans et al. BMC Ophthalmology  (2018) 18:250 Page 4 of 7Results
Clinical, demographic and genotype data for all six
probands are summarized in Table 1. There was no
family history of SCD in two pedigrees; however, in
family 3 the disease status of the proband’s mother was
unavailable. The corneal phenotypes were diverse and
included anterior and mid-stromal crystalline deposits,
diffuse stromal haze and arcus lipoides (Fig. 1). There
was an incremental accumulation of corneal deposits
with age, and the corneal changes were symmetric in
all individuals. There were corneal crystals in all pro-
bands, although these deposits were minimal in some
individuals (Fig. 1 g, h). Corneal crystals were present
at slit lamp examination of proband 2 at age 6 years,
but neither parent had signs of corneal disease. The
patient was re-examined at the age 8 years, when an
increase in the corneal crystals was noted (Fig. 1b), but
the visual acuity had remained unchanged (Table 1).
Corneal imaging highlighted the presence of crystals.
With SD-OCT there were highly reflective deposits in
the anterior stroma of probands 1 and 2 (Fig. 1c, d), with
confocal microscopy there were bright reflective crystal-
line deposits identified in the anterior stroma of proband
2 (Fig. 2e). On confocal microscopy small round deposits
were also identified in the superficial epithelial cells
(Fig. 2a), in and around anterior stromal keratocytes
(Fig. 2d) and in mid-stroma (Fig. 2f). The basal epithelialFig. 2 Corneal confocal microscopy imaging in an 8-year old child with Sc
hyperreflective deposits (arrows) in the left eye (a). Normal appearance of t
right eye (c). Hyper-reflective deposits within and around keratocytes (arrow
Hyper-reflective deposits in mid-stroma in the left eye (f), but with unaffeccells, sub-epithelial nerves, posterior stroma and corneal
endothelium all appeared normal (Fig. 2b, c, g, h).
Coexisting systemic disease was present in some pro-
bands. Proband 5 and her affected sister both had bilat-
eral knee deformities, although their affected mother
was normal (Fig. 3). In proband 1 a fasting lipid profile
showed high levels of total cholesterol (5.72 mmol/l;
normal values in adults < 5.17 mmol/l) [16] and in pro-
bands 2 and 3 there was a borderline elevation of total
cholesterol to 4.89 mmol/l and 5.00 mmol/l, respectively
(normal values in children < 4.40 mmol/l) [17].
A novel c.527G>A; p.(Gly176Glu) variant, predicted to
be pathogenic or probably pathogenic by all six bioinfor-
matic tools (Table 3), was identified in proband 1 of
Czech origin. The amino acid residue Gly-176 is highly
conserved and located in the transmembrane domain of
UBIAD1, therefore a mutation is likely to disrupt the
transmembrane helices and active site [18]. Czech
proband 2 harboured a known UBIAD1 c.289G>A;
p.(Ala97Thr) mutation. This variant was absent in both
parents, suggesting a de novo origin that was confirmed
by paternity testing. The white British probands had pre-
viously reported mutations c.361C>T; p.(Leu121Phe)
[19] and c.308C>T; p.(Thr103Ile) [6]. Two reportedly
unrelated British families of South Asian origin, both
harboured a known c.305G>A; p.(Asn102Ser) mutation
[19–21]. Pedigrees and segregation of the respectivehnyder corneal dystrophy. Superficial epithelial cells with small round
he basal epithelial cell layer (b), and subepithelial nerve plexus in the
s) (d) and needle-shaped crystals in anterior stroma of the left eye (e).
ted posterior stroma (g) and endothelium in the left eye (h)
Fig. 3 Pedigrees of the six families with Schnyder corneal dystrophy. Sequence electropherograms of the identified heterozygous mutations in
UBIAD1 are also shown. The mutation arose de novo in family 2. Probands are indicated by an arrow and examined individuals by an asterisk.
Mutation status in tested subjects is shown +/− for those who are heterozygous for a mutation in UBIAD1 and −/− for those who do not carry
the pathogenic variant. Individuals known to be affected by Schnyder corneal dystrophy are shown in black, whereas a question mark indicates
that the disease status of the individual was unknown
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None of the UBIAD1 pathogenic changes found in the
current study were observed in the gnomAD dataset or
in the Czech control population. All of the in silico algo-
rithms predicted that the detected mutations were
pathogenic or likely pathogenic, except for SNP&GOprediction for previously reported variant c.361C>T;
p.(Leu121Phe) [19] (Table 3).
Discussion
In this study we report the phenotype and genotype of six
families with SCD. Five different UBIAD1 mutations were
Table 3 In silico analysis of UBIAD1 missense variants identified in patients with Schnyder corneal dystrophy in the current study
MutPred Polyphen2 PROVEAN SNP&GO SIFT MutationTaster
p.(Ala97Thr) Disease Probably damaging Disease Disease Disease Disease
p.(Leu121Phe) Disease Probably damaging Disease Benign Disease Disease
p.(Thr103Ile) Possibly damaging Probably damaging Disease Disease Disease Disease
p.(Asn102Ser) Disease Probably damaging Disease Disease Disease Disease
p.(Gly176Glu) Possibly damaging Probably damaging Disease Disease Disease Disease
Six different algorithms were used; tolerated and neutral scores are indicated in green as benign; yellow indicates a possibly damaging variant, and red was used
for a probably damaging and disease-causing mutation
As for MutPred an overall probability score > 0.5 was considered as possibly damaging and a score > 0.75 was considered as disease-causing. NM_013319.2,
NP_037451.1 and ENST00000376810.5 were used as reference sequences
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c.527G>A; p.(Gly176Glu), was novel. The youngest pro-
band was found to harbour a de novo c.289G>A;
p.(Ala97Thr) mutation, previously identified in an
Irish-French family [18]. To the best of our knowledge,
this is only the second observation of a spontaneously oc-
curring mutation in an SCD patient [6]. The family history
provided by proband 3 also indicated possible de novo oc-
currence of the identified mutation, but unfortunately this
could not be confirmed as parental DNA samples were
unavailable.
The c.305G>A; p.(Asn102Ser) mutation, identified in two
South Asian probands, is the most frequently occurring
UBIAD1 mutation. It has been reported in several popula-
tions including the Czech Republic, Poland, Taiwan and
China, supporting the hypothesis that it is a mutation hot-
spot [19–22]. One white British proband had a c.361C>T;
p.(Leu121Phe) mutation, previously observed in three SCD
families from the UK, America and Saudi Arabia [19, 23].
The c.308C>T; p.(Thr103Ile) mutation, detected in one
white British individual, has previously been described in a
proband of Japanese-European descent [6].
The clinical course of SCD is associated with characteris-
tic corneal opacities that increase with age. Initially, central
corneal haze and/or crystals are present; this was observed
in our youngest proband, who was 6 years old when first
examined. Arcus lipoides typically develops in the third
decade, followed by mid-peripheral corneal haze in the late
fourth decade [24], as documented in the current case
series (probands 1, 4–5). Corneal crystals are present in ap-
proximately 50% of patients with SCD [2]. Interestingly,
crystals were found in all six of our probands, although in
two probands the area of crystal deposit was very small.
However, the number of individuals we examined is rela-
tively low compared with prior studies [2].
Confocal microscopy has previously been performed in
two children with SCD, both at a similar age as our pro-
band 2 [25]. Our findings corroborate observations of ac-
cumulation of crystal/reflective material in anterior
stroma, both intra- and extracellularly. Interestingly, un-
like the previous study, subepithelial nerves appeared nor-
mal and we were able to detect tiny reflective deposits inthe corneal epithelium. Electron microscopy of corneas
with SCD has also documented lipid accumulation inside
epithelial cells [26, 27].
The differential diagnosis of crystalline corneal depos-
ition includes monoclonal gammopathy and cystinosis.
These conditions should be considered in any individual
with corneal crystals who does not have a family history
of SCD. Laboratory investigation should be guided by
the presence of associated symptoms and patient age.
Dyslipidemia and genu valgum have been reported to be
associated with SCD [3, 28]. Three of the six probands in
this study had fasting serum lipid testing. Total cholesterol
was elevated in one proband and borderline levels were
found in the other two probands. Self-reported knee de-
formities were only present in proband 5 and her sister, al-
though their mother was not affected, which may indicate
that other genetic or environmental factors influence the
expression of this trait.
Conclusions
SCD should be considered in the differential diagnosis of
any unexplained corneal haze and/or crystal deposition,
even in the absence of a family history of corneal disease.
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